Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1221-1240 of 2,120 trials

X-Linked Hypohidrotic Ectodermal Dysplasia: ER004 Treatment

We are studying a new prenatal treatment for male infants with X-linked hypohidrotic ectodermal dysplasia to see if it improves sweating ability and dental health. The trial also examines the safety of this treatment for both the infants and their mothers.

X-linked Hypohidrotic Ectodermal Dysplasia≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicinePediatrics

Mantle Cell Lymphoma: Ibrutinib and Venetoclax Study

We are studying the effects of Ibrutinib alone and in combination with Venetoclax in patients with untreated mantle cell lymphoma. The goal is to see how well these treatments reduce disease levels in the body.

Untreated Mantle Cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Infectious Pulmonary Endotheliopathy: Iloprost Infusion Study

We are investigating whether a continuous infusion of iloprost can help reduce the risk of death in mechanically ventilated patients with infectious pulmonary issues. This study compares the treatment to a placebo to assess its effectiveness.

Respiratory FailureInfectious Pulmonary Endotheliopathy>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Thyroid Eye Disease: Batoclimab Extension Study

We are studying the long-term effects of batoclimab in people with Thyroid Eye Disease who previously participated in earlier studies. The goal is to see if it continues to help reduce eye bulging and benefits those who didn't respond to earlier treatments.

Thyroid Eye Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

Sickle Cell Disease and β-Thalassemia: CTX001 Treatment Study

We are studying the long-term safety and effectiveness of a new CRISPR-based treatment for patients with β-thalassemia or severe sickle cell disease. This research aims to understand how well the treatment works over time.

Sickle Cell DiseaseTransfusion Dependent ThalassemiaConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia

We are studying different conditioning treatments for children and adolescents with acute lymphoblastic leukemia undergoing stem cell transplantation. Our goal is to find out which treatment leads to better survival and fewer side effects.

Acute Lymphoblastic Leukaemia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Cardio Renal Syndrome: Peritoneal Ultrafiltration Treatment

We are studying whether Peritoneal Ultrafiltration can help prevent heart failure worsening in patients with Cardio Renal Syndrome. The trial also looks at improvements in health and quality of life.

Congestive Heart Failure>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrology

Advanced Melanoma: EIK1001 and Pembrolizumab Study

We are studying a new treatment combining EIK1001 with pembrolizumab for patients with advanced melanoma. The goal is to see if this combination improves survival and slows disease progression compared to a placebo.

Advanced Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteOncology

Wiskott-Aldrich Syndrome: Gene Therapy Follow-Up

We are monitoring the long-term safety of a gene therapy in patients with Wiskott-Aldrich Syndrome who received a specific stem cell treatment. This study helps us understand how the therapy affects their health over time.

Wiskott-Aldrich Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematology

Systemic Juvenile Idiopathic Arthritis: Sarilumab Study

We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.

Systemic Juvenile Idiopathic Arthritis (sJIA)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Relapsing Multiple Sclerosis: Obexelimab Study

We are testing a new medication, Obexelimab, to see if it helps prevent new brain lesions in people with relapsing multiple sclerosis. The study will also assess the safety of this treatment compared to a placebo.

Relapsing-Remitting Multiple Sclerosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Relapsing Multiple Sclerosis: YTB323 Treatment Study

We are testing a new treatment called YTB323 for people with Relapsing Multiple Sclerosis who have had ongoing disease activity despite previous therapies. The study aims to assess its safety and effects on disease progression.

Relapsing Multiple Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurology

INZ-701 for ENPP1 and ABCC6 Deficiency

We are studying the long-term safety of INZ-701 in patients with ENPP1 and ABCC6 deficiencies. This trial will help us understand how the drug works over time and its effects on certain blood markers.

Pseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/Phosphodiesterase 1 DeficiencyGeneralized Arterial Calcification of InfancyEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

Colon Cancer: HIPEC with Mitomycin-C Study

We are investigating whether adding a special chemotherapy during surgery helps prevent cancer recurrence in patients with colon cancer that has spread to the abdomen. This study compares outcomes for those receiving this treatment versus standard care.

Peritoneal Metastases of Colorectal Cancer>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesOncology

Pain Relief for First-Degree Perineal Tears: Emla Cream vs. Injection

We are comparing a topical cream to an injection for pain relief in women with first-degree perineal tears after childbirth. The goal is to see which method provides better comfort during and after the repair.

First-Degree Perineal Laceration6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Multiple Myeloma: Venetoclax and Dexamethasone Study

We are investigating whether a combination of venetoclax and dexamethasone is effective for patients with relapsed and refractory multiple myeloma who have the translocation (11;14). This study aims to find out if this treatment can improve outcomes for these patients.

Multiple Myeloma>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesHematologyOncology

Acute Myeloid Leukemia: Revumenib with Azacitidine and Venetoclax

We are studying whether adding revumenib to azacitidine and venetoclax helps adults with newly diagnosed NPM1-mutated AML who cannot receive intensive chemotherapy. The goal is to see if this combination improves survival and treatment response.

Acute Myeloid LeukemiaConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOncology

Acute Myeloid Leukemia: Ivosidenib, Azacitidine, and Venetoclax Study

We are investigating whether adding venetoclax to ivosidenib and azacitidine helps patients with newly diagnosed IDH1-mutated AML who cannot undergo intensive chemotherapy. The goal is to see if this combination improves survival and remission rates.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOncology

Septic Shock: Landiolol Infusion Study

We are investigating whether Landiolol can improve blood flow and heart function in patients with septic shock. This study compares its effects to standard treatments for managing rapid heart rates.

Microcirculatory Abnormalities in Septic Shock>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Advanced Solid Tumors: VERT-002 Study

We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology